Se-Hoon Lee, Ph.D. - Publications

Affiliations: 
2011 University of Texas at Austin, Austin, Texas, U.S.A. 
Area:
Nanotechnology, Electronics and Electrical Engineering

88 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Keam B, Lee KW, Lee SH, Kim JS, Kim JH, Wu HG, Eom KY, Kim S, Ahn SH, Chung EJ, Kwon SK, Jeong WJ, Jung YH, Kim JW, Heo DS. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. The Oncologist. PMID 30796155 DOI: 10.1634/theoncologist.2019-0070  0.4
2018 Park SE, Noh JM, Kim YJ, Lee HS, Cho JH, Lim SW, Ahn YC, Pyo H, Choi YL, Han J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. EGFR Mutation is Associated with Short Progression Free Survival in Patients with Stage III Non-Squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 29914238 DOI: 10.4143/crt.2018.125  0.32
2018 Lee SH, Lee B, Shim JH, Lee KW, Yun JW, Kim SY, Kim TY, Kim YH, Ko YH, Chung HC, Yu CS, Lee J, Rha SY, Kim TW, Jung KH, et al. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 29690749 DOI: 10.4143/crt.2018.132  0.32
2018 Park BJ, Cho JH, Lee JH, Shin S, Kim HK, Choi YS, Zo JI, Shim YM, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K, Kim J. Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy. Lung Cancer (Amsterdam, Netherlands). 117: 7-13. PMID 29496256 DOI: 10.1016/j.lungcan.2018.01.004  0.32
2017 Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, et al. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. Bmc Cancer. 17: 646. PMID 28899363 DOI: 10.1186/s12885-017-3641-6  0.32
2017 Cho M, Ahn S, Hong M, Bang H, Van Vrancken M, Kim S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Sun JM, Lee SH, Ahn MJ, ... ... Lee S, et al. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. Oncotarget. PMID 28477007 DOI: 10.18632/oncotarget.17199  0.4
2016 Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. The Korean Journal of Internal Medicine. PMID 27097770 DOI: 10.3904/kjim.2014.259  0.4
2016 Park S, Park S, Lee SH, Suh B, Ock CY, Keam B, Kim TM, Kim DW, Kim YW, Heo DS. Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. Cancer Biomarkers : Section a of Disease Markers. 16: 425-33. PMID 27062699 DOI: 10.3233/CBM-160581  0.4
2016 Sim SH, Beom SH, Ahn YO, Keam B, Kim TM, Lee SH, Kim DW, Heo DS. Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors. Thoracic Cancer. 7: 161-6. PMID 27042217 DOI: 10.1111/1759-7714.12304  0.4
2016 Park S, Park S, Lee SH, Suh B, Keam B, Kim TM, Kim DW, Kim YW, Heo DS. Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. The Korean Journal of Internal Medicine. PMID 27017943 DOI: 10.3904/kjim.2015.062  0.4
2016 Ock CY, Keam B, Kim TM, Han DH, Won TB, Lee SH, Hah JH, Kwon TK, Kim DW, Kim DY, Rhee CS, Wu HG, Sung MW, Heo DS. Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. The Korean Journal of Internal Medicine. PMID 26976150 DOI: 10.3904/kjim.2015.020  0.36
2016 Cha S, Lee J, Shin JY, Kim JY, Sim SH, Keam B, Kim TM, Kim DW, Heo DS, Lee SH, Kim JI. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. Bmc Cancer. 16: 170. PMID 26925973 DOI: 10.1186/s12885-016-2209-1  0.4
2016 Heo H, Kim S, Lee HH, Cho HR, Xu WJ, Lee SH, Park CK, Park S, Choi SH, Kim H. On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel. Plos One. 11: e0147794. PMID 26820720 DOI: 10.1371/journal.pone.0147794  0.4
2016 Yang Y, Lim O, Kim TM, Ahn YO, Choi HN, Chung H, Min B, Her JH, Cho SY, Keam B, Lee SH, Kim DW, Hwang YK, Heo DS. Phase I study of random, healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors. Cancer Immunology Research. PMID 26787822 DOI: 10.1158/2326-6066.CIR-15-0118  0.36
2016 Ham JS, Kim S, Kim HK, Byeon S, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Han J, Park W, Ahn MJ. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: e1-4. PMID 26762749 DOI: 10.1016/j.jtho.2015.09.013  0.4
2016 Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, et al. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget. PMID 26755650 DOI: 10.18632/oncotarget.6874  0.36
2015 Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, Kim HS, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Park W, Ahn MJ. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26749488 DOI: 10.1016/j.jtho.2015.12.093  0.36
2015 Lee SH, Park K. The MISSION: Impossible? No, the Journey Should Continue with Better Targeting! Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 1667-9. PMID 26709476 DOI: 10.1097/JTO.0000000000000701  0.4
2015 Han JJ, Kim DW, Koh J, Keam B, Kim TM, Jeon YK, Lee SH, Chung DH, Heo DS. Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 26707383 DOI: 10.1016/j.cllc.2015.11.006  0.36
2015 Lee JY, Sun JM, Oh DR, Lim SH, Goo J, Lee SH, Kim SB, Park KU, Kim HK, Hong DS, Kim JS, Kim SG, Yi SY, Yun HJ, Hyun MS, et al. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 26705681 DOI: 10.1016/j.radonc.2015.11.030  0.32
2015 Lee DY, Won JK, Lee SH, Park DJ, Jung KC, Sung MW, Wu HG, Kim KH, Park YJ, Hah JH. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid : Official Journal of the American Thyroid Association. PMID 26541309 DOI: 10.1089/thy.2015.0316  0.36
2015 Kim TM, Song A, Kim DW, Kim S, Ahn YO, Keam B, Jeon YK, Lee SH, Chung DH, Heo DS. Mechanisms of Acquired Resistance to AZD9291, a Mutation-Selective, Irreversible EGFR Inhibitor. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26473643 DOI: 10.1097/JTO.0000000000000688  0.4
2015 Yoo DH, Song SW, Yun TJ, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Park CK, Kim IH, Choi SH. MR Imaging Evaluation of Intracerebral Hemorrhages and T2 Hyperintense White Matter Lesions Appearing after Radiation Therapy in Adult Patients with Primary Brain Tumors. Plos One. 10: e0136795. PMID 26322780 DOI: 10.1371/journal.pone.0136795  0.4
2015 Lee KW, Koh Y, Kim SB, Shin SW, Kang JH, Wu HG, Sung MW, Keam B, Kim DW, Kim TM, Kim KH, Kwon TK, Hah JH, Kim IA, Ahn SH, ... ... Lee SW, ... ... Lee SH, et al. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. The Oncologist. PMID 26304911 DOI: 10.1634/theoncologist.2015-0208  0.4
2015 Sunwoo L, Choi SH, Yoo RE, Kang KM, Yun TJ, Kim TM, Lee SH, Park CK, Kim JH, Park SW, Sohn CH, Won JK, Park SH, Kim IH. Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. Neuroradiology. PMID 26232204 DOI: 10.1007/s00234-015-1569-6  0.4
2015 Kim M, Ku JH, Kwak C, Kim HH, Lee E, Keam B, Kim TM, Heo DS, Lee SH, Moon KC. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. Plos One. 10: e0133371. PMID 26200905 DOI: 10.1371/journal.pone.0133371  0.4
2015 Keam B, Lee SJ, Kim TM, Paeng JC, Lee SH, Kim DW, Jeon YK, Chung DH, Kang KW, Chung JK, Heo DS. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 1189-94. PMID 26200273 DOI: 10.1097/JTO.0000000000000569  0.4
2015 Park S, Nam SJ, Keam B, Kim TM, Jeon YK, Lee SH, Hah JH, Kwon TK, Kim DW, Sung MW, Heo DS, Bang YJ. VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 26194375 DOI: 10.4143/crt.2015.093  0.36
2015 Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM, Lee SH, Min HS, Kim YT, Kim DW, Jeon YK, Chung DH. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 26183759 DOI: 10.1038/modpathol.2015.63  0.4
2015 Kim BS, Kim SK, Choi SH, Lee SH, Seol HJ, Nam DH, Lee JI, Park CK, Kong DS. Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. Journal of Neuro-Oncology. 124: 101-10. PMID 26026859 DOI: 10.1007/s11060-015-1808-z  0.4
2015 Kim JE, Cho HR, Xu WJ, Kim JY, Kim SK, Kim SK, Park SH, Kim H, Lee SH, Choi SH, Park S, Park CK. Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas. Oncotarget. PMID 26008980  0.4
2015 Kim JY, Lee SH, Moon KC, Kwak C, Kim HH, Keam B, Kim TM, Heo DS. The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma. The Journal of Urology. PMID 25997916 DOI: 10.1016/j.juro.2015.04.114  0.4
2015 Beom SH, Kim DW, Sim SH, Keam B, Park JH, Lee JO, Kim TM, Lee SH, Heo DS. Gefitinib-induced Interstitial Lung Disease in Korean Lung Cancer Patients. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 25761482 DOI: 10.4143/crt.2014.201  0.36
2015 Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, Heo DS, Yuasa M, Yanagihara Y, Bang YJ. Phase I study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 25715763 DOI: 10.4143/crt.2014.249  0.4
2015 Song A, Kim TM, Kim DW, Kim S, Keam B, Lee SH, Heo DS. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2379-87. PMID 25688157 DOI: 10.1158/1078-0432.CCR-14-1350  0.4
2015 Choi Y, Keam B, Kim TM, Lee SH, Kim DW, Heo DS. Cancer Treatment Near the End-of-life Becomes More Aggressive: Changes in Trend During 10 Years at a Single Institute. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 25687851 DOI: 10.4143/crt.2014.200  0.4
2015 Park S, Keam B, Kim SH, Kim KH, Kim YJ, Kim JS, Kim TM, Lee SH, Kim DW, Lee JS, Heo DS. Pemetrexed Singlet versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-Small Cell Lung Cancer Patients with EGFR Mutations. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 25687850 DOI: 10.4143/crt.2014.244  0.4
2015 Lee YG, Lee E, Kim I, Lee KW, Kim TM, Lee SH, Kim DW, Heo DS. Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 25672586 DOI: 10.4143/crt.2014.045  0.4
2015 Keam B, Kim S, Ahn YO, Kim TM, Lee SH, Kim DW, Heo DS. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Research. 35: 175-82. PMID 25550549  0.4
2015 Lee JK, Kim DW, Keam B, Kim TM, Lee SH, Kim YJ, Heo DS. The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 47: 182-8. PMID 25544584 DOI: 10.4143/crt.2013.227  0.4
2015 Yoo KE, Kang RY, Lee JY, Lee YJ, Suh SY, Kim KS, Kim HS, Lee SH, Lee BK. Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 23: 1969-77. PMID 25500718 DOI: 10.1007/s00520-014-2547-y  0.4
2015 Koh J, Cho H, Kim H, Kim SI, Yun S, Park CK, Lee SH, Choi SH, Park SH. IDH2 mutation in gliomas including novel mutation. Neuropathology : Official Journal of the Japanese Society of Neuropathology. 35: 236-44. PMID 25495392 DOI: 10.1111/neup.12187  0.4
2015 Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 544-52. PMID 25424851 DOI: 10.1158/1078-0432.CCR-14-1756  0.36
2015 Sim SH, Kim YJ, Kim SH, Keam B, Kim TM, Lee SH, Kim DW, Heo DS, Lee JS. Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 141: 1073-81. PMID 25410789 DOI: 10.1007/s00432-014-1875-0  0.4
2015 Keam B, Ha H, Kim TM, Jeon YK, Lee SH, Kim DW, Kim CW, Heo DS. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leukemia & Lymphoma. 1-7. PMID 25382617 DOI: 10.3109/10428194.2014.982642  0.4
2015 Yun TJ, Park CK, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Choi SH. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. Radiology. 274: 830-40. PMID 25333475 DOI: 10.1148/radiol.14132632  0.4
2015 Kim M, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, Lee JS, Jeon YK, Kim CW, Heo DS. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). Annals of Hematology. 94: 437-44. PMID 25300500 DOI: 10.1007/s00277-014-2228-4  0.4
2015 Wen H, Cho HR, Yun T, Kim H, Park CK, Lee SH, Choi SH, Park S. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. Journal of Neurochemistry. 132: 183-93. PMID 25251602 DOI: 10.1111/jnc.12950  0.4
2015 Lee S, Choi SH, Ryoo I, Yoon TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. Journal of Neuro-Oncology. 121: 141-50. PMID 25205290 DOI: 10.1007/s11060-014-1614-z  0.4
2015 An YJ, Cho HR, Kim TM, Keam B, Kim JW, Wen H, Park CK, Lee SH, Im SA, Kim JE, Choi SH, Park S. An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients. International Journal of Cancer. Journal International Du Cancer. 136: 162-71. PMID 24798643 DOI: 10.1002/ijc.28949  0.4
2015 Lim YJ, Kim IH, Han TJ, Choi SH, Park SH, Park CK, Paek SH, Lee SH, Kim TM. Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features. International Journal of Clinical Oncology. 20: 21-8. PMID 24705988 DOI: 10.1007/s10147-014-0690-6  0.4
2014 Ock CY, Keam B, Lim Y, Kim TM, Lee SH, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. Head & Neck. PMID 26104823 DOI: 10.1002/hed.23891  0.4
2014 Myung JK, Cho HJ, Kim H, Park CK, Lee SH, Choi SH, Park P, Yoon JM, Park SH. Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status. Translational Oncology. 7: 712-9. PMID 25500080 DOI: 10.1016/j.tranon.2014.10.002  0.4
2014 Lee DW, Shin DY, Kim JW, Keam B, Kim TM, Kim HJ, Kim DW, Wu HG, Paek SH, Kim YW, Heo DS, Kim DG, Lee SH. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score. Lung Cancer (Amsterdam, Netherlands). 86: 363-8. PMID 25453849 DOI: 10.1016/j.lungcan.2014.10.001  0.4
2014 Kim JH, Choi SH, Ryoo I, Yun TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging. Plos One. 9: e113587. PMID 25419975 DOI: 10.1371/journal.pone.0113587  0.4
2014 Lee JL, Park SH, Koh SJ, Lee SH, Kim YJ, Choi YJ, Lee J, Lim HY. Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program. Cancer Chemotherapy and Pharmacology. 74: 1005-13. PMID 25193433 DOI: 10.1007/s00280-014-2579-5  0.4
2014 Kwon J, Chie EK, Kim K, Kim HJ, Wu HG, Kim IH, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Ha SW. Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. Journal of Korean Medical Science. 29: 1094-101. PMID 25120319 DOI: 10.3346/jkms.2014.29.8.1094  0.4
2014 Bae SH, Park MJ, Lee MM, Kim TM, Lee SH, Cho SY, Kim YH, Kim YJ, Park CK, Kim CY. Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. Journal of Korean Medical Science. 29: 980-4. PMID 25045231 DOI: 10.3346/jkms.2014.29.7.980  0.4
2014 Kim BH, Kim IH, Park SH, Park CK, Jung HW, Kim TM, Lee SH, Heo DS. Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 46: 261-9. PMID 25038761 DOI: 10.4143/crt.2014.46.3.261  0.4
2014 Lee HJ, Heo DS, Cho JY, Han SW, Chang HJ, Yi HG, Kim TE, Lee SH, Oh DY, Im SA, Jang IJ, Bang YJ. A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 46: 234-42. PMID 25038758 DOI: 10.4143/crt.2014.46.3.234  0.4
2014 Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS. Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 46: 323-30. PMID 25036571 DOI: 10.4143/crt.2013.120  0.4
2014 Sim SH, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS. The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 140: 2135-42. PMID 25005787 DOI: 10.1007/s00432-014-1768-2  0.4
2014 Kim BH, Kim HJ, Wu HG, Kang CH, Kim YT, Lee SH, Kim DW. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis. Clinical Lung Cancer. 15: 356-64. PMID 24996882 DOI: 10.1016/j.cllc.2014.05.005  0.4
2014 Shin DY, Kim DW, Keam B, Kim TM, Lee SH, Kang CH, Kim YT, Heo DS. The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: a retrospective cohort study. Lung Cancer (Amsterdam, Netherlands). 85: 320-5. PMID 24954359 DOI: 10.1016/j.lungcan.2014.05.021  0.4
2014 Park CK, Lee SH, Kim JY, Kim JE, Kim TM, Lee ST, Choi SH, Park SH, Kim IH. Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget. 5: 3399-407. PMID 24930669  0.4
2014 Kim YJ, Kim SJ, Lee JK, Choi WS, Park JH, Kim HJ, Sim SH, Lee KW, Lee SH, Kim JH, Kim DW, Lee JS, Bang YJ, Heo DS. Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis. Journal of Cancer Research and Clinical Oncology. 140: 1567-74. PMID 24793643 DOI: 10.1007/s00432-014-1688-1  0.4
2014 Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. Jama. 311: 1430-7. PMID 24715074 DOI: 10.1001/jama.2014.3314  0.4
2014 Lee SH, Bang YJ, Mainwaring P, Ng C, Chang JW, Kwong P, Li RK, Sriuranpong V, Toh CK, Yuan J, Pitman Lowenthal S, Chung HC. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. Asia-Pacific Journal of Clinical Oncology. 10: 237-45. PMID 24576311 DOI: 10.1111/ajco.12163  0.4
2014 Baek SH, Kim H, Lee J, Kim DK, Oh KH, Kim YS, Han JS, Kim TM, Lee SH, Joo KW. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. The Korean Journal of Internal Medicine. 29: 40-8. PMID 24574832 DOI: 10.3904/kjim.2014.29.1.40  0.4
2014 Jung JW, Kang HR, Lee SH, Cho SH. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. Oncology. 86: 127-34. PMID 24480856 DOI: 10.1159/000357711  0.4
2014 Lee YG, Kim I, Lee E, Bang SM, Kang CH, Kim YT, Kim HJ, Wu HG, Kim YW, Kim TM, Lee KW, Lee SH, Kim DW, Heo DS. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. Thrombosis and Haemostasis. 111: 1112-20. PMID 24477503 DOI: 10.1160/TH13-11-0956  0.4
2014 Go SI, Keam B, Kim TM, Lee SH, Kim DW, Kim HJ, Wu HG, Chung DH, Heo DS. Clinical significance of downstaging in patients with limited-disease small-cell lung cancer. Clinical Lung Cancer. 15: e1-6. PMID 24356090 DOI: 10.1016/j.cllc.2013.09.003  0.4
2014 Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. International Journal of Clinical Oncology. 19: 594-600. PMID 23912954 DOI: 10.1007/s10147-013-0602-1  0.4
2014 Kim TM, Kim S, Ahn YO, Lee SH, Kim DW, Heo DS. Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. Leukemia & Lymphoma. 55: 940-3. PMID 23772641 DOI: 10.3109/10428194.2013.813505  0.4
2013 Kim JW, Koh Y, Kim DW, Ahn YO, Kim TM, Han SW, Oh DY, Lee SH, Im SA, Kim TY, Heo DS, Bang YJ. Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 45: 325-33. PMID 24454005 DOI: 10.4143/crt.2013.45.4.325  0.4
2013 Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS. How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 45: 178-85. PMID 24155676 DOI: 10.4143/crt.2013.45.3.178  0.4
2013 Go H, Kim DW, Kim D, Keam B, Kim TM, Lee SH, Heo DS, Bang YJ, Chung DH. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 1445-50. PMID 24128715 DOI: 10.1097/JTO.0b013e3182a4dd6e  0.4
2013 Song YS, Choi SH, Park CK, Yi KS, Lee WJ, Yun TJ, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Jahng GH, Chang KH. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis. Korean Journal of Radiology. 14: 662-72. PMID 23901325 DOI: 10.3348/kjr.2013.14.4.662  0.4
2013 Yoon HJ, Paeng JC, Kwak C, Park YH, Kim TM, Lee SH, Chung JK, Edmund Kim E, Lee DS. Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy. Annals of Nuclear Medicine. 27: 748-55. PMID 23818007 DOI: 10.1007/s12149-013-0742-4  0.4
2013 Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 1069-74. PMID 23804027 DOI: 10.1097/JTO.0b013e318294c8e8  0.4
2013 Park CK, Kim JH, Nam DH, Kim CY, Chung SB, Kim YH, Seol HJ, Kim TM, Choi SH, Lee SH, Heo DS, Kim IH, Kim DG, Jung HW. A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. Neuro-Oncology. 15: 1096-101. PMID 23800677 DOI: 10.1093/neuonc/not069  0.4
2013 Chu HH, Choi SH, Ryoo I, Kim SC, Yeom JA, Shin H, Jung SC, Lee AL, Yoon TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, et al. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Radiology. 269: 831-40. PMID 23771912 DOI: 10.1148/radiol.13122024  0.4
2013 Lee JH, Wu HG, Kim HJ, Park CI, Lee SH, Kim DW, Heo DS. Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer. Radiation Oncology Journal. 31: 18-24. PMID 23620865 DOI: 10.3857/roj.2013.31.1.18  0.4
2013 Hur S, Chung JW, Kim HC, Oh DY, Lee SH, Bang YJ, Kim WH. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. Journal of Vascular and Interventional Radiology : Jvir. 24: 947-56; quiz 957. PMID 23602421 DOI: 10.1016/j.jvir.2013.02.030  0.4
2013 Lee JK, Im SA, Lee D, Kim JY, Lim Y, Lee E, Moon HG, Kim TY, Han SW, Oh DY, Lee SH, Han W, Kim DW, Kim TY, Noh DY. Efficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors. Journal of Breast Cancer. 16: 66-71. PMID 23593084 DOI: 10.4048/jbc.2013.16.1.66  0.4
2013 Lim Y, Keam B, Koh Y, Kim TM, Lee SH, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS, Kim KH. Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 116: 55-60. PMID 23570665 DOI: 10.1016/j.oooo.2013.02.007  0.4
2013 Keam B, Im SA, Lim Y, Han SW, Moon HG, Oh DY, Cho N, Lee SH, Han W, Moon WK, Kim DW, Kim TY, Park IA, Noh DY. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer. Annals of Surgical Oncology. 20: 2242-9. PMID 23529780 DOI: 10.1245/s10434-012-2756-x  0.4
2013 Kim YH, Park CK, Kim TM, Choi SH, Kim YJ, Choi BS, Han JH, Lee SH, Kim CY, Kim IA, Heo DS, Kim IH, Kim DG, Jung HW. Seizures during the management of high-grade gliomas: clinical relevance to disease progression. Journal of Neuro-Oncology. 113: 101-9. PMID 23459994 DOI: 10.1007/s11060-013-1094-6  0.4
Show low-probability matches.